Terms: = Bone cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Clinical Outcome
2 results:
1. Differences between zoledronic acid and denosumab for breast cancer treatment.
Ishikawa T
J Bone Miner Metab; 2023 May; 41(3):301-306. PubMed ID: 36879056
[TBL] [Abstract] [Full Text] [Related]
2. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the iris study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract] [Full Text] [Related]